Aura Biosciences Announces the Presentation of Phase 2 End of Study Data Evaluating Suprachoroidal Administration of Bel-sar for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at The Retina Society Annual Meeting

BOSTON, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies to treat a range of solid tumors designed to preserve organ function, today announced that Phase 2 end of study data evaluating suprachoroidal administration of bel-sar for the first-line treatment of patients with small choroidal melanoma and indeterminate lesions will be presented at The Retina Society Annual Meeting being held September 11-15, 2024, in Lisbon, Portugal.

Read more at globenewswire.com